In Vivo Performance of Fenofibrate Formulated With Ordered Mesoporous Silica Versus 2-Marketed Formulations: A Comparative Bioavailability Study in Beagle Dogs-Reference-Cited by-同舟云学术

In Vivo Performance of Fenofibrate Formulated With Ordered Mesoporous Silica Versus 2-Marketed Formulations: A Comparative Bioavailability Study in Beagle Dogs

Published:2016-08 Issue:8 Volume:105 Page:2381-2385
ISSN:0022-3549
Container-title:Journal of Pharmaceutical Sciences
language:en
Short-container-title:Journal of Pharmaceutical Sciences

Author:

Bukara Katarina,Schueller Laurent,Rosier Jan,Daems Tinne,Verheyden Loes,Eelen Siemon,Martens Johan A.,Van den Mooter Guy,Bugarski Branko,Kiekens Filip

Funder

Formac Pharmaceuticals NV

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference17 articles.

1. Micronized fenofibrate: a new fibric acid hypolipidemic agent;Guay;Ann Pharmacoter,1993

2. Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters on hypertrigliceridemic patients with low levels of high density lipoprotein cholesterol in the fed and fasted state;Genest;J Cardiovasc Pharmacol,2000

3. Characterization and dissolution of fenofibrate solid dispersion systems;Ming-Thau;Int J Pharm,1994

4. Enhanced oral bioavailability of fenofibrate using polymeric nanoparticulated systems: physicochemical characterization and in vivo investigation;Yousaf;Int J Nanomed,2015

5. Gastrointestinal behavior of nano- and microsized fenofibrate: in vivo evaluation in man and in vitro simulation by assessment of the permeation potential;Hens;Eur J Pharm Sci,2015

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biopharmaceutical advancement of efonidipine hydrochloride ethanolate through amorphous solid dispersion of a Parteck SLC mesoporous silica polymer;RSC Pharmaceutics;2024

2. Processability of mesoporous materials in fused deposition modeling for drug delivery of a model thermolabile drug;International Journal of Pharmaceutics: X;2023-12

3. Study of Disordered Mesoporous Silica Regarding Intrinsic Compound Affinity to the Carrier and Drug-Accessible Surface Area;Molecular Pharmaceutics;2023-11-10

4. Understanding Fenofibrate Release from Bare and Modified Mesoporous Silica Nanoparticles;Pharmaceutics;2023-05-30

5. Mesoporous silica nanoparticles: Their potential as drug delivery carriers and nanoscavengers in Alzheimer's and Parkinson's diseases;Saudi Pharmaceutical Journal;2023-03